Send us a message
Study Start‑Up
What We Offer: Full-Service Study Start-Up Support
We understand that delays in study activation can lead to higher costs and slower patient access to innovative therapies. That’s why our clinical study start-up team in Mississippi works closely with sponsors, CROs, and investigators to handle every detail, from documentation to training and logistics.
With Covalent, you’re not just choosing a site. You’re choosing a partner with deep local knowledge and a proven track record.
How We Support Your Study Start-Up
Our study start-up specialists in Mississippi offer focused, hands-on support to ensure no detail is overlooked. From regulatory coordination to staff preparation, we streamline every step of the process. Our specialists are deeply familiar with the local community and are equipped to support both single-site and multi-site studies with precision and efficiency.
Regulatory & IRB Coordination
We manage submissions, respond to queries, and ensure compliance with timelines and local regulations.
Site & Staff Readiness
Our team ensures that investigators and staff are trained, equipped, and prepared for study launch from day one.
Frequently Asked Questions
Our team is always available to walk you through the start-up process. Here are a few common questions we get:
What does a study start-up specialist do?
A Study Start-Up (SSU) specialist coordinates between sponsors, regulatory bodies, and sites to prepare clinical trials for launch. They manage site selection, regulatory submissions, contracts, and training so that studies begin on time and comply with all regulations.
How quickly can Covalent activate a study site?
With established processes and strong community relationships, we’re able to move efficiently. Timelines vary by protocol, but we aim for rapid, quality-focused activation.
Do you only provide clinical study start-up in Mississippi?
Currently, yes. Our focus is on clinical study start-up in Mississippi, where we offer deep local knowledge, strong physician partnerships, and access to diverse patient populations.
